表紙
市場調査レポート

2017年までの睡眠障害市場:ジェネリック医薬品の登場とパイプラインの弱体化が市場にマイナスの影響

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

発行 GBI Research 商品コード 189222
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
2017年までの睡眠障害市場:ジェネリック医薬品の登場とパイプラインの弱体化が市場にマイナスの影響 Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
出版日: 2011年04月11日 ページ情報: 英文 141 Pages
概要

睡眠障害市場は急速に成長してきました。不眠症は、作業場での慢性的障害の主な要因と考えられてきました。2010年、睡眠障害市場は35億米ドルとなりましたが、2017年には34億米ドルに減少する見込みです。その主な原因が不眠症市場です。不眠症治療薬市場はこれまで急速に拡大してきましたが、2011〜2017年は3.8%減となる見込みです。競争が激しく、新規参入に対する障壁があるためです。こうした状況が、下肢静止不能症候群、ナルコレプシー、睡眠時無呼吸症候群などの分野にも波及しています。

当レポートでは、睡眠障害市場について分析し、市場の概要と地域別、治療分野別動向、新製品開発パイプライン、競合動向、業界内でのM&A動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
  • 睡眠障害治療薬市場の収益予測
    • 収益
    • 年間治療費
    • 治療使用形態

第4章 地域別環境

  • 地域別収益分析
    • 米国
    • 欧州5カ国
    • 日本

第5章 治療分野

  • 不眠症
  • 下肢静止不能症候群
  • ナルコレプシー
  • 睡眠時無呼吸症候群

第6章 パイプライン分析

  • イントロダクション
  • 研究開発パイプライン:睡眠障害
  • 不眠症
  • 下肢静止不能症候群
  • ナルコレプシー
  • 睡眠時無呼吸症候群

第7章 競合環境

  • 市場シェア分析
  • 競合プロファイリング

第8章 M&A環境

  • 睡眠障害市場
  • 合併・買収
  • ライセンシング契約
  • 共同開発

第9章 付録

目次
Product Code: GBIHC095MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market”, which provides insights into sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders R&D pipeline. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatments is also presented.

Scope

The report covers -
•  Data and analysis on the sleep disorders therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
•  Annualized market data for the sleep disorders therapeutics market from 2002 to 2010, with forecasts to 2017.
•  Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
•  Key drivers and restraints that have had a significant impact on the market.
•  The competitive landscape of the global sleep disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Sanofi-aventis, King pharmaceuticals, questcor pharmaceuticals, Novartis, GlaxoSmithKline, plc, Pfizer and Boehringer Ingelheim
•  Key M&A activities and Licensing Agreements that took place in 2008 and 2010 in the sleep disorders therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
•  Build effective strategies to launch their pipeline products by identifying potential geographies.
•  Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
•  Develop key strategic initiatives by studying the key strategies of top competitors.
•  Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
•  Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Executive Summary

GBI Research, the leading business intelligence provider has released its latest research “Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market”, which essentially provides insights on sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders treatments across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatment is also presented.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

High Growth Rate and Increasing Necessity for CNS Drugs has Made the Sleep Disorder Market Attractive

The sleep disorders market has been a fast growing market, with insomnia considered to be the prime factor for chronic disability in the workforce. In 2010, the Sleep Disorders Market was worth $3.5 billion, which is forecast to decrease to $3.4 billion by 2017, with a rate of -0.4% between 2010 and 2017. This is mainly affected by insomnia, which is a leading indication among all types of sleep disorders.

The insomnia therapeutics market has been growing at a fast pace over the past few years, but is expected to decline with a rate of -3.8% from 2011 to 2017 due to high competition in the market, which will be a barrier for prospective entrants. This competition can be transmitted over other indications in the market such as restless leg syndrome, narcolepsy and sleep apnea. This can be carried out by practicing patient awareness about the diseases and types of treatments, while the other method is by increasing diagnosis.

Sleep Disorders Market, Revenue Forecasts ($bn), 2002-2017

Source: GBI Research

The Insomnia Market will Decline Moderately Due to Patent Expirations

The insomnia therapeutics market was a growing market during 2002-2009, and the growth was dominated by the US market. The growth rate is likely to decline from 2011 onwards due to the impact of patent expiry of key drugs. However, new branded drugs will minimize the impact of generic erosion to some extent. This impact will be seen due to patent expiries in the insomnia market, as it accounts for approximately 79% share of the global market. The global insomnia therapeutics market is expected to decline at a CAGR of -3.8%, from $2.8 billion in 2010 to $2.1 billion in 2017. The major causes for decline in the market are patent expiries of major drugs and weak profile of current pipeline molecules. The global insomnia therapeutics market in 2010 was worth $2.8 billion, which was primarily formed of three brands, namely Lunesta (eszopiclone), Paxil (paroxetine) and Ambien (zolpidem). The cost of therapy for branded products is in the range of $750 to $1,002 for duration of six months, as compared to those of generics which is between $10 and $20 for the same duration. The most popular product for insomnia was Ambien (including generics and (Controlled Releases [CRs]), which demonstrates the large extent to which older generation products have been successful in terms of satisfying market demand. Ambien was approved for short term treatment of insomnia, while Ambien CR was approved for prescription for up to six months in 1991. The Average Selling Price (ASP) of products in the market is in the
Restless Leg Syndrome, Narcolepsy and Sleep Apnea are Dominated by Late-Stage Pipeline Molecules that will Boost the Competition

The restless leg syndrome, narcolepsy and sleep apnea pipeline portfolios have 12, five and 11 molecules across the different developmental stages, respectively. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 79% of the total number of pipeline programs. This indicates that the imminent launch of these drugs could increase the sleep disorder market value.

The restless leg syndrome market has a strong pipeline that will support the growth of this market, thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as UCB Group, GlaxoSmithKline plc, axxonis Pharma AG, Ligand Pharmaceuticals Incorporated, National Institute of Neurological Disorders and Stroke, Kyowa Hakko Kirin Co., Ltd., Jazz Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Omeros Corporation and Manhattan Pharmaceuticals, Inc., are actively developing molecules for restless leg syndrome.

The entry of pipeline molecules will boost the sleep disorder therapeutics market, thereby bringing about further rises in the sleep disorder therapeutics market in the coming years. Rapid entry of new players and highly active pipelines will intensify competition.

Sleep Disorder Therapeutics Market, R&D Pipeline by Phase (%), 2004-2010

Source: GBI Research’s Internal Database, Company Websites, Clinicaltrials.gov

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 9
2 Sleep Disorders Market: Introduction 11
2.1 GBI Research Report Guidance 12
3 Sleep Disorders Market to 2017: Market Overview 13
3.1 Introduction 13
3.2 Revenue Forecasts for the Sleep Disorder Therapeutics Market 14
3.2.1 Revenue 14
3.2.2 Annual Cost of Treatment (ACT) 15
3.2.3 Treatment Usage Patterns 17
4 Sleep Disorders Market to 2017: Geographical Landscape 23
4.1 Revenue Analysis by Geography 23
4.2 The US 25
4.2.1 Revenue 25
4.2.2 Annual Cost of Treatment 26
4.2.3 Treatment Usage Patterns 28
4.3 Top Five Countries of Europe 35
4.3.1 Revenue 35
4.3.2 Annual Cost of Treatment 36
4.3.3 Treatment Usage Patterns 37
4.4 Japan 43
4.4.1 Revenue 43
4.4.2 Annual Cost of Treatment 44
4.4.3 Treatment Usage Patterns 45
5 Sleep Disorders Market: Therapeutic Landscape 51
5.1 Insomnia Therapeutics Market 51
5.1.1 Introduction 51
5.1.2 Revenue 52
5.1.3 Annual Cost of Treatment 53
5.1.4 Treatment Usage Patterns 54
5.1.5 Drivers and Barriers for the Insomnia Therapeutics Market 60
5.2 Restless Leg Syndrome Therapeutics Market 61
5.2.1 Introduction 61
5.2.2 Revenue 62
5.2.3 Annual Cost of Treatment 63
5.2.4 Treatment Usage Patterns 64
5.2.5 Drivers and Barriers for the Restless Leg Syndrome Therapeutics Market 70
5.3 Narcolepsy Therapeutics Market 71
5.3.1 Introduction 71
5.3.2 Revenue 72
5.3.3 Annual Cost of Treatment 73
5.3.4 Treatment Usage Patterns 74
5.3.5 Drivers and Barriers for the Narcolepsy Therapeutics Market 80
5.4 Sleep Apnea Therapeutics Market 81
5.4.1 Introduction 81
5.4.2 Revenue 82
5.4.3 Annual Cost of Treatment 83
5.4.4 Treatment Usage Patterns 84
5.4.5 Drivers and Barriers for the Sleep Apnea Therapeutics Market 90
6 Sleep Disorders Market to 2017: Pipeline Analysis 92
6.1 Introduction 92
6.2 Research and Development Pipeline - Sleep Disorders 93
6.3 Insomnia - Pipeline Analysis 93
6.3.1 Introduction 93
6.3.2 Insomnia Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 94
6.3.3 Filed Molecules 95
6.3.4 Phase III 95
6.3.5 Phase II 96
6.3.6 Phase I 97
6.3.7 Preclinical Phase 97
6.3.8 Discovery Phase 97
6.4 Restless Leg Syndrome Therapeutics Market: Pipeline Analysis 98
6.4.1 Introduction 98
6.4.2 Narcolepsy Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 99
6.5 Narcolepsy Therapeutics Market - Pipeline Analysis 100
6.5.1 Introduction 100
6.5.2 Narcolepsy Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 101
6.6 Sleep Apnea Therapeutics Market - Pipeline Analysis 102
6.6.1 Introduction 102
6.6.2 Sleep Apnea Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 103
7 Sleep Disorder Market to 2016: Competitive Landscape 104
7.1 Overview 104
7.2 Competitive Profiling 104
7.2.1 Sanofi-Aventis 104
7.2.2 King Pharmaceuticals, Inc. 107
7.2.3 Questcor Pharmaceuticals, Inc. 108
7.2.4 Novartis 109
7.2.5 GlaxoSmithKline plc 111
7.2.6 Pfizer 113
7.2.7 Boehringer Ingelheim 115
7.2.8 Cephalon Pharmaceuticals 119
7.2.9 Schwarz Pharma 121
7.2.10 Mylan Pharma 125
8 Sleep Disorders Market to 2017: M&A Landscape 127
8.1 Sleep Disorders Market 127
8.1.1 Overview: Deals by Type 127
8.1.2 Deals by Year 128
8.2 Mergers and Acquisitions 128
8.2.1 Overview 128
8.2.2 Meda Acquires Commercialization Rights of Sublinox and OX-NLA from Orexo 128
8.2.3 Eli Lilly Acquires Hypnion 129
8.2.4 Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical 129
8.2.5 Sciele Pharma Acquires Alliant Pharmaceuticals 130
8.2.6 Jazz Pharmaceuticals Acquires Orphan Medical 130
8.2.7 Paul Royalty Acquires US Royalty Rights of Estorra from Aventis 130
8.3 Licensing Agreements 132
8.3.1 GlaxoSmithKline (GSK) and Actelion Pharmaceuticals 132
8.3.2 Purdue Pharma Enters into License Agreement with Transcept Pharmaceuticals 132
8.3.3 Neurocrine Biosciences Enters into Licensing Agreement with Dainippon Sumitomo Pharma 133
8.3.4 Eli Lilly Enters into Licensing Agreement with Merck 133
8.3.5 ECR Pharmaceuticals Enters into License Agreement with NovaDel Pharma 133
8.3.6 Vanda Enters into Licensing Agreement with Bristol-Myers Squibb 134
8.4 Co-Development Strategies 135
9 Sleep Disorders Market: Appendix 136
9.1 Market Definition 136
9.2 Abbreviations 136
9.3 Research Methodology 137
9.3.1 Coverage 137
9.3.2 Secondary Research 137
9.3.3 Forecasting 138
9.3.4 Primary Research 140
9.3.5 Expert Panels 140
9.4 Contact Us 140
9.5 Disclaimer 141
9.6 Sources 141

1.1 List of Tables
Table 1: Sleep Disorders Market, Global, Revenue ($bn), 2002-2010 14
Table 2: Sleep Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017 14
Table 3: Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2002-2010 16
Table 4: Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2010-2017 16
Table 5: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2002-2010 17
Table 6: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2010-2017 18
Table 7: Sleep Disorders Market, Global, Diseased Population (millions), 2002-2010 19
Table 8: Sleep Dis orders Market, Global, Diseased Population (millions), 2010-2017 19
Table 9: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2002-2010 20
Table 10: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2010-2017 20
Table 11: Sleep Disorders Market, Global, Diagnosed Population (million), 2002-2010 21
Table 12: Sleep Disorders Market, Global, Diagnosed Population (million), 2010-2017 21
Table 13: Sleep Disorders Market, Global, Prescription Population (million), 2002-2010 22
Table 14: Sleep Disorders Market, Global, Prescription Population (million), 2010-2017 22
Table 15: Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 24
Table 16: Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 24
Table 17: Sleep Disorders Market, the US, Revenue ($bn), 2002-2010 25
Table 18: Sleep Disorders Market, the US, Revenue Forecasts ($bn), 2010-2017 25
Table 19: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2002-2010 27
Table 20: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2010-2017 27
Table 21: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2002-2010 28
Table 22: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2010-2017 29
Table 23: Sleep Disorders Market, the US, Diseased Population (millions), 2002-2010 30
Table 24: Sleep Disorders Market, the US, Diseased Population (millions), 2010-2017 30
Table 25: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2002-2010 32
Table 26: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2010-2017 32
Table 27: Sleep Disorders Market, the US, Diagnosed Population (millions), 2002-2010 33
Table 28: Sleep Disorders Market, the US, Diagnosed Population (millions), 2010-2017 33
Table 29: Sleep Disorders Market, the US, Prescription Population (millions), 2002-2010 34
Table 30: Sleep Disorders Market, the US, Prescription Population (millions), 2010-2017 34
Table 31: Sleep Disorders Market, Top Five EU Countries, Revenue ($bn), 2002-2010 35
Table 32: Sleep Disorders Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2017 35
Table 33: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2002-2010 36
Table 34: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2010-2017 36
Table 35: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2002-2010 37
Table 36: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2010-2017 38
Table 37: Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions), 2002-2010 39
Table 38: Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions), 2010-2017 39
Table 39: Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (millions), 2002-2010 40
Table 40: Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (millions), 2010-2017 40
Table 41: Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions), 2002-2010 41
Table 42: Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions), 2010-2017 41
Table 43: Sleep Disorders Market, Top Five Countries in Europe, Prescription Population (millions), 2002-2010 42
Table 44: Sleep Disorders Market, Top Five Countries in Europe, Prescription Population (millions), 2010-2017 42
Table 45: Sleep Disorders Market, Japan, Revenue ($bn), 2002-2010 43
Table 46: Sleep Disorders Market, Japan, Revenue Forecast ($bn), 2010-2017 43
Table 47: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2010 44
Table 48: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2010-2017 44
Table 49: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2002-2010 45
Table 50: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2010-2017 46
Table 51: Sleep Disorders Market, Japan, Diseased Population (millions), 2002-2010 47
Table 52: Sleep Disorders Market, Japan, Diseased Population (millions), 2010-2017 47
Table 53: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2002-2010 48
Table 54: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2010-2017 48
Table 55: Sleep Disorders Market, Japan, Diagnosed Population (millions), 2002-2010 49
Table 56: Sleep Disorders Market, Japan, Diagnosed Population (millions), 2010-2017 49
Table 57: Sleep Disorders Market, Japan, Prescription Population (millions), 2002-2010 50
Table 58: Sleep Disorders Market, Japan, Prescription Population (millions), 2010-2017 50
Table 59: Insomnia Therapeutics Market, Global, Revenue ($bn), 2002-2010 52
Table 60: Insomnia Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 52
Table 61: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 53
Table 62: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 53
Table 63: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 54
Table 64: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 55
Table 65: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2002-2010 56
Table 66: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2010-2017 56
Table 67: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010 57
Table 68: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017 57
Table 69: Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010 58
Table 70: Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017 58
Table 71: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2002-2010 59
Table 72: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2010-2017 59
Table 73: Restless Leg Syndrome Therapeutics Market, Global, Revenue ($bn), 2002-2010 62
Table 74: Restless Leg Syndrome Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 62
Table 75: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 63
Table 76: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017 63
Table 77: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 64
Table 78: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 65
Table 79: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2002-2010 66
Table 80: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2010-2017 66
Table 81: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010 67
Table 82: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017 67
Table 83: Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010 68
Table 84: Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017 68
Table 85: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2002-2010 69
Table 86: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2010-2017 69
Table 87: Narcolepsy Therapeutics Market, Global, Revenue ($m), 2002-2010 72
Table 88: Narcolepsy Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017 72
Table 89: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 73
Table 90: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 73
Table 91: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010 74
Table 92: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2017 75
Table 93: Narcolepsy Therapeutics Market, Global, Diseased Population (thoousands), 2002-2010 76
Table 94: Narcolepsy Therapeutics Market, Global, Diseased Population (thoousands), 2010-2017 76
Table 95: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2002-2010 77
Table 96: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2010-2017 77
Table 97: Narcolepsy Therapeutics Market, Global, Diagnosed Population (thousands), 2002-2010 78
Table 98: Narcolepsy Therapeutics Market, Global, Diagnosed Population (thousands), 2010-2017 78
Table 99: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2002-2010 79
Table 100: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2010-2017 79
Table 101: Sleep Apnea Therapeutics Market, Global, Revenue ($m), 2002-2010 82
Table 102: Sleep Apnea Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017 82
Table 103: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 83
Table 104: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 83
Table 105: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 84
Table 106: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 85
Table 107: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2010 86
Table 108: Sleep Apnea Therapeutics Market, Global, Diseased Population (millions), 2010-2017 86
Table 109: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010 87
Table 110: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017 87
Table 111: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010 88
Table 112: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017 88
Table 113: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2010 89
Table 114: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2010-2017 89
Table 115: Insomnia Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules 95
Table 116: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase III 95
Table 117: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase II 96
Table 118: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase I 97
Table 119: Insomnia Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase 97
Table 120: Insomnia Therapeutics Market, Global, Pipeline Analysis, Discovery Phase 97
Table 121: Restless Leg Syndrome Therapeutics Market, Global, Pipeline Analysis 99
Table 122: Narcolepsy Therapeutics Market, Global, Pipeline Analysis 101
Table 123: Restless Leg Syndrome Therapeutics Market, Global, Pipeline Analysis 103
Table 124: Sleep Disorders Market, Global, Major M&A Deals, 2004-2010 131

1.2 List of Figures
Figure 1: Sleep Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017 14
Figure 2: Sleep Disorders Market, Annual Cost of Treatment ($), 2002-2017 15
Figure 3: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2002-2017 17
Figure 4: Sleep Disorders Market, Global, Diseased Population (millions), 2002-2017 19
Figure 5: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2002-2017 20
Figure 6: Sleep Disorders Market, Global, Diagnosis Population (million), 2002-2017 21
Figure 7: Sleep Disorders Market, Global, Prescription Population (million), 2002-2017 22
Figure 8: Sleep Disorders Market, Global, Revenue Analysis by Geography ($m), 2002-2017 23
Figure 9: Sleep Disorders Market, the US, Revenue Forecasts ($bn), 2002-2017 25
Figure 10: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2002-2017 26
Figure 11: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2002-2017 28
Figure 12: Sleep Disorders Market, the US, Diseased Population (millions), 2002-2017 30
Figure 13: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2002-2017 31
Figure 14: Sleep Disorders Market, the US, Diagnosis Population (millions), 2002-2017 33
Figure 15: Sleep Disorders Market, the US, Prescription Population (millions), 2002-2017 34
Figure 16: Sleep Disorders Market, Top Five EU Countries, Revenue Forecasts ($bn), 2002-2017 35
Figure 17: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2002-2017 36
Figure 18: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2002-2017 37
Figure 19: Sleep Disorders Market, Top Five Countries in the EU, Diseased Population (millions), 2002-2017 39
Figure 20: Sleep Disorders Market, Top Five Countries in the EU, Treatment Seeking Population (millions), 2002-2017 40
Figure 21: Sleep Disorders Market, Top Five Countries in the EU, Diagnosis Population (millions), 2002-2017 41
Figure 22: Sleep Disorders Market, Top Five Countries in the EU, Prescription Population (millions), 2002-2017 42
Figure 23: Sleep Disorders Market, Japan, Revenue Forecast ($bn), 2002-2017 43
Figure 24: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2017 44
Figure 25: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2002-2017 45
Figure 26: Sleep Disorders Market, Japan, Diseased Population (millions), 2002-2017 47
Figure 27: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2002-2017 48
Figure 28: Sleep Disorders Market, Japan, Diagnosis Population (millions), 2002-2017 49
Figure 29: Sleep Disorders Market, Japan, Prescription Population (millions), 2002-2017 50
Figure 30: Insomnia Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 52
Figure 31: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 53
Figure 32: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 54
Figure 33: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2002-2017 56
Figure 34: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 57
Figure 35: Insomnia Therapeutics Market, Global, Diagnosis Population (millions), 2002-2017 58
Figure 36: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2002-2017 59
Figure 37: Insomnia Therapeutics Market, Global, Market Drivers and Barriers, 2010-2017 60
Figure 38: Restless Leg Syndrome Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 62
Figure 39: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 63
Figure 40: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 64
Figure 41: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2002-2017 66
Figure 42: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 67
Figure 43: Restless Leg Syndrome Therapeutics Market, Global, Diagnosis Population (millions), 2002-2017 68
Figure 44: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2002-2017 69
Figure 45: Restless Leg Syndrome, Therapeutics Market, Drivers and Barriers, 2010-2017 70
Figure 46: Narcolepsy Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 72
Figure 47: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 73
Figure 48: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2017 74
Figure 49: Narcolepsy Therapeutics Market, Global, Diseased Population (thousands), 2002-2017 76
Figure 50: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2002-2017 77
Figure 51: Narcolepsy Therapeutics Market, Global, Diagnosis Population (thousands), 2002-2017 78
Figure 52: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2002-2017 79
Figure 53: Narcolepsy Therapeutics Market, Global, Drivers and Barriers, 2010-2017 80
Figure 54: Sleep Apnea Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 82
Figure 55: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 83
Figure 56: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 84
Figure 57: Sleep Apnea Therapeutics Market, Global, Diseased Population (millions), 2002-2017 86
Figure 58: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 87
Figure 59: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017 88
Figure 60: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2017 89
Figure 61: Sleep Apnea Therapeutics, Market Drivers and Barriers, 2010-2017 90
Figure 62: Sleep Disorders Market, Global, R&D Pipeline by Indications (%), 2010 92
Figure 63: Sleep Disorders Market, Global, R&D Pipeline by Phase (%), 2010 93
Figure 64: Insomnia Therapeutics Market, Global, Pipeline by Phase and Class, 2010 94
Figure 65: Restless Leg Syndrome Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 98
Figure 66: Narcolepsy Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 100
Figure 67: Sleep Apnea Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 102
Figure 68: SWOT Analysis of Sanofi-Aventis 106
Figure 69: SWOT Analysis of King Pharmaceuticals, Inc. 107
Figure 70: SWOT Analysis of Questcor Pharmaceuticals 108
Figure 71: SWOT Analysis of Novartis 110
Figure 72: SWOT Analysis of GlaxoSmithKline 112
Figure 73: SWOT Analysis of Pfizer 114
Figure 74: SWOT Analysis of Boehringer Ingelheim GmbH 118
Figure 75: SWOT Analysis of Cephalon Pharmaceuticals 120
Figure 76: SWOT Analysis of Schwarz Pharma 124
Figure 77: SWOT Analysis of Mylan Pharma 126
Figure 78: Sleep Disorders Market, Global, Deals by Type, 2004-2010 127
Figure 79: Sleep Disorders Market, Global, Major Deals By Year, 2008-2010 128
Figure 80: Sleep Disorder Market, Global, Major Deals By Geography, 2004-2010 134
Figure 81: Sleep Disorder Market, Global, Co-Development Strategies By Geography, 2004-2010 135
Figure 82: GBI Research Market Forecasting Model 139

Back to Top